HK1123302A1 - Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them - Google Patents

Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them

Info

Publication number
HK1123302A1
HK1123302A1 HK09102736.6A HK09102736A HK1123302A1 HK 1123302 A1 HK1123302 A1 HK 1123302A1 HK 09102736 A HK09102736 A HK 09102736A HK 1123302 A1 HK1123302 A1 HK 1123302A1
Authority
HK
Hong Kong
Prior art keywords
manufacture
pharmaceutical compositions
receptor antagonists
thrombin receptor
tricyclic thrombin
Prior art date
Application number
HK09102736.6A
Other languages
English (en)
Inventor
Samuel Chackalamannil
William J Greenlee
Yuguang Wang
Yan Xia
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1123302(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HK1123302A1 publication Critical patent/HK1123302A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09102736.6A 2002-04-16 2009-03-23 Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them HK1123302A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
HK1123302A1 true HK1123302A1 (en) 2009-06-12

Family

ID=29250954

Family Applications (3)

Application Number Title Priority Date Filing Date
HK05103479A HK1070887A1 (en) 2002-04-16 2005-04-22 Tricyclic thrombin receptor antagonists
HK09102736.6A HK1123302A1 (en) 2002-04-16 2009-03-23 Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
HK09108388.4A HK1129893A1 (en) 2002-04-16 2009-09-14 Tricyclic thrombin receptor antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK05103479A HK1070887A1 (en) 2002-04-16 2005-04-22 Tricyclic thrombin receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09108388.4A HK1129893A1 (en) 2002-04-16 2009-09-14 Tricyclic thrombin receptor antagonist

Country Status (34)

Country Link
US (3) US7304078B2 (xx)
EP (5) EP2062890B1 (xx)
JP (2) JP4558331B2 (xx)
KR (1) KR101026929B1 (xx)
CN (1) CN1659162B (xx)
AR (1) AR039570A1 (xx)
AT (3) ATE378330T1 (xx)
AU (1) AU2003221932B2 (xx)
BR (1) BRPI0309309B8 (xx)
CA (1) CA2482858C (xx)
CY (3) CY1107184T1 (xx)
DE (3) DE60317493T3 (xx)
DK (2) DK2065384T3 (xx)
EC (1) ECSP045368A (xx)
ES (3) ES2357876T3 (xx)
FR (1) FR15C0047I2 (xx)
HK (3) HK1070887A1 (xx)
IL (1) IL164585A (xx)
LT (1) LTC1495018I2 (xx)
LU (1) LU92759I2 (xx)
MX (1) MXPA04010308A (xx)
MY (1) MY144040A (xx)
NL (1) NL300746I1 (xx)
NO (2) NO330500B1 (xx)
NZ (2) NZ575139A (xx)
PE (1) PE20040412A1 (xx)
PL (1) PL214718B1 (xx)
PT (2) PT1495018E (xx)
RU (2) RU2329264C9 (xx)
SG (1) SG164279A1 (xx)
SI (2) SI1495018T1 (xx)
TW (1) TWI343919B (xx)
WO (1) WO2003089428A1 (xx)
ZA (1) ZA200408342B (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CA2567981C (en) * 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
JP2008515908A (ja) * 2004-10-06 2008-05-15 ユニバーシティー オブ ロチェスター 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療
PT1848705E (pt) * 2005-01-14 2010-05-10 Schering Corp Sínteses exo- e diastereo-selectivas de análogos da himbacina
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
WO2006076565A2 (en) * 2005-01-14 2006-07-20 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
EP1853592B1 (en) * 2005-01-14 2011-03-02 Schering Corporation Synthesis of himbacine analogs
US7772276B2 (en) 2005-01-14 2010-08-10 Schering Corporation Exo-selective synthesis of himbacine analogs
WO2006105217A2 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
CN101384259A (zh) * 2005-12-22 2009-03-11 先灵公司 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
EP2007755B1 (en) * 2006-04-13 2012-06-27 Schering Corporation Fused ring thrombin receptor antagonists
AR061664A1 (es) * 2006-06-29 2008-09-10 Schering Corp Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
JP2010505842A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体
WO2008060372A2 (en) * 2006-10-04 2008-05-22 Schering Corporation Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
EP2120879A2 (en) * 2006-12-22 2009-11-25 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
PT2240487E (pt) 2008-02-05 2012-03-08 Sanofi Sa Triazolopiridazinas como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
RU2494100C2 (ru) 2008-02-05 2013-09-27 Санофи-Авентис Соли триазолия в качестве ингибиторов par1, их получение и применение в качестве лекарственного средства
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
EP2805939B1 (en) 2008-05-19 2018-06-27 Merck Sharp & Dohme Corp. Heterocyclic compounds as factor IXA inhibitors.
PL2438060T3 (pl) 2009-06-04 2014-03-31 Merck Sharp & Dohme Aktywny metabolit antagonisty receptora trombiny
WO2010144339A2 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
ES2532902T3 (es) 2010-04-16 2015-04-01 Sanofi Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015013083A1 (en) * 2013-07-22 2015-01-29 Merck Sharp & Dohme Corp. Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
WO2015026693A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
EP3035928B1 (en) 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EP3131897B8 (en) 2014-04-16 2022-08-03 Merck Sharp & Dohme LLC Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
CN107304200B (zh) * 2016-04-22 2021-09-21 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CN116133660A (zh) 2020-07-22 2023-05-16 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
ZA9810685B (en) * 1997-11-25 1999-12-23 Schering Corp Thrombin receptor antagonists.
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US6645987B2 (en) * 2000-06-15 2003-11-11 Schering Corporation Nor-seco himbacine derivatives useful as thrombin receptor antagonists
MY139335A (en) 2001-10-18 2009-09-30 Schering Corp Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

Also Published As

Publication number Publication date
BRPI0309309B1 (pt) 2018-09-04
BR0309309A (pt) 2005-02-15
NL300746I2 (xx) 2016-01-21
EP1495018B3 (en) 2011-03-16
CY1111363T1 (el) 2015-08-05
EP1495018A1 (en) 2005-01-12
RU2008106401A (ru) 2009-08-27
CN1659162A (zh) 2005-08-24
ATE378330T1 (de) 2007-11-15
US7304078B2 (en) 2007-12-04
DE60317493D1 (en) 2011-01-13
EP1860106A1 (en) 2007-11-28
TW200404068A (en) 2004-03-16
CN1659162B (zh) 2011-08-31
CY2015029I2 (el) 2016-04-13
US20030216437A1 (en) 2003-11-20
KR20040099441A (ko) 2004-11-26
PE20040412A1 (es) 2004-07-12
DE60317493T2 (de) 2008-09-18
PT1495018E (pt) 2008-02-19
HK1129893A1 (en) 2009-12-11
AU2003221932A1 (en) 2003-11-03
FR15C0047I1 (xx) 2015-08-28
US20070179187A1 (en) 2007-08-02
EP1982984B1 (en) 2013-02-13
NZ535880A (en) 2007-11-30
DE60335679D1 (de) 2011-02-17
CA2482858A1 (en) 2003-10-30
TWI343919B (en) 2011-06-21
EP1982984A3 (en) 2008-10-29
ECSP045368A (es) 2005-01-03
CY2015029I1 (el) 2016-04-13
NO20044963L (no) 2004-11-15
EP2065384B1 (en) 2011-01-05
EP1982984A2 (en) 2008-10-22
ES2297150T7 (es) 2012-03-16
NO2015016I2 (no) 2015-07-09
EP1495018B1 (en) 2007-11-14
CA2482858C (en) 2010-11-30
CY1107184T1 (el) 2012-10-24
EP2062890B1 (en) 2011-01-05
JP2005528406A (ja) 2005-09-22
IL164585A (en) 2010-11-30
AU2003221932B2 (en) 2007-11-22
DK1495018T3 (da) 2008-02-18
PL214718B1 (pl) 2013-09-30
ES2357876T3 (es) 2011-05-03
PT2065384E (pt) 2011-03-16
US20070270439A1 (en) 2007-11-22
JP4558331B2 (ja) 2010-10-06
EP1860106B1 (en) 2010-01-20
NO2015016I1 (no) 2015-07-20
ES2297150T3 (es) 2008-05-01
NL300746I1 (xx) 2016-01-21
MXPA04010308A (es) 2005-02-03
LU92759I2 (en) 2015-08-31
ZA200408342B (en) 2006-05-31
DE60317493T3 (de) 2018-07-12
AR039570A1 (es) 2005-02-23
ATE455774T1 (de) 2010-02-15
JP2010132710A (ja) 2010-06-17
ATE494284T1 (de) 2011-01-15
BRPI0309309B8 (pt) 2021-05-25
KR101026929B1 (ko) 2011-04-04
SI1495018T1 (sl) 2008-04-30
MY144040A (en) 2011-07-29
DK2065384T3 (da) 2011-05-02
SG164279A1 (en) 2010-09-29
EP2065384A1 (en) 2009-06-03
RU2004133375A (ru) 2005-07-10
RU2329264C9 (ru) 2009-04-20
NZ575139A (en) 2010-08-27
LTC1495018I2 (lt) 2017-04-10
PL373332A1 (en) 2005-08-22
US7713999B2 (en) 2010-05-11
FR15C0047I2 (fr) 2016-05-06
HK1070887A1 (en) 2005-06-30
SI2065384T1 (sl) 2011-05-31
WO2003089428A1 (en) 2003-10-30
NO330500B1 (no) 2011-05-02
RU2329264C2 (ru) 2008-07-20
IL164585A0 (en) 2005-12-18
EP2062890A1 (en) 2009-05-27
DE60331114D1 (de) 2010-03-11
ES2338171T3 (es) 2010-05-04

Similar Documents

Publication Publication Date Title
HK1123302A1 (en) Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
HUP0500443A3 (en) Himbacine analogues as thrombin receptor antagonists and pharmaceutical compositions containing them
AU2003240947A8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1490062E (pt) Miméticos de glucocorticóides, métodos para a sua preparação, composições farmacêuticas e suas utilizações
HUP0303081A3 (en) Thrombin receptor antagonists, pharmaceutical compositions containing them and their use
TWI340138B (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
HK1088543A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
EP1594467A4 (en) MISUSE OF PHARMACEUTICAL COMPOSITIONS OF OPIOIDES AND OTHER MEDICAMENTS
HK1210032A1 (en) Compositions and methods of delivery of pharmacological agents
HUP0303651A3 (en) N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor and pharmaceutical compositions containing them
PT1585548T (pt) Composições e métodos de administração de agentes farmacológicos
HUP0302382A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HUP0304058A2 (hu) Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
IL176384A (en) Pyrrolidinochlorinated basazole and pharmacy preparations containing them
HUP0401656A3 (en) Mch antagonists for the treatment of obesity and pharmaceutical compositions containing them
EP1808446A4 (en) IL-18 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION WITH THE ANTAGONIST
HUP0402019A3 (en) Piperidine derivatives useful as ccr5 antagonists and pharmaceutical compositions containing them
PL1664050T3 (pl) Neuroprotekcyjne związki bicykliczne i zawierające je kompozycje farmaceutyczne
TWI315983B (en) Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
HUP0302003A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HUP0302614A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HUP0400389A3 (en) Aryl oxime-piperazines useful as ccr5 antagonists and pharmaceutical compositions containing them
AU2003231019A8 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
IL157398A0 (en) Pharmaceutical compositions comprising ccr5 antagonists
IL148292A0 (en) Pharmaceutical compositions of halofuginone and other quinazolinone derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220419